Outcome of hospital care of liver disease associated with hepatitis C in the United States

被引:81
作者
Kim, WR [1 ]
Gross, JB [1 ]
Poterucha, JJ [1 ]
Locke, GR [1 ]
Dickson, ER [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Outcomes Res Unit, Rochester, MN 55905 USA
关键词
D O I
10.1053/jhep.2001.20798
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We describe mortality and resource utilization for inpatient care of hepatitis C (HCV) in comparison to alcohol-induced liver disease (ALD) in the United States and identify factors that affect outcomes. The Healthcare Cost and Utilization Project database, a national inpatient sample was used to identify hospitalization records with diagnoses related to liver disease from HCV and ALD. Outcome of hospitalizations was analyzed in terms of in-hospital deaths and health care resource utilization. For 1995, we estimate that there were 26,700 hospitalizations and 2,600 deaths in acute, nonfederal hospitals in the United States for liver diseases caused by HCV. Total charges for these hospitalizations were $514 million. In comparison, ALD was associated with 101,200 hospitalizations, 13,400 deaths, and $1.8 billion in charges. Simultaneous HCV and alcohol abuse was associated with younger ages at the time of hospitalization and death compared with HCV or ALD alone. In a logistic regression analysis, alcohol abuse (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.2-1.5) and human immunodeficiency virus (HIV) infection (OR, 4.5; 95% CI, 4.0-4.9) were associated with an increased risk of death among those with HCV. Liver transplantation and patient death were associated with the largest increase in hospitalization charges. Major complications of cirrhosis, such as variceal bleeding, encephalopathy, and hepatorenal syndrome, and sociodemographic factors, such as race and health insurance, were also significantly associated with the risk of death and hospitalization charges, which were similar in HCV and ALD. This study provides new estimates regarding the public health impact of HCV, for use in health policy decisions and cost-effectiveness analyses of preventive and therapeutic interventions.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 20 条
[1]
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]
[Anonymous], 1998, EC COSTS ALCOHOL DRU
[3]
[Anonymous], NATL VITAL STAT REPO
[4]
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy [J].
Bonkovsky, HL ;
Woolley, JM .
HEPATOLOGY, 1999, 29 (01) :264-270
[5]
BROWN DM, 1994, DIGESTIVE DIS US EPI, P67
[6]
Hepatitis C viral infection in the immunosuppressed patient [J].
Collier, J ;
Heathcote, J .
HEPATOLOGY, 1998, 27 (01) :2-6
[7]
Hepatitis C [J].
Di Bisceglie, AM .
LANCET, 1998, 351 (9099) :351-355
[8]
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis [J].
Foster, GR ;
Goldin, RD ;
Thomas, HC .
HEPATOLOGY, 1998, 27 (01) :209-212
[9]
Gross JB, 1998, MAYO CLIN PROC, V73, P355
[10]
Hepatitis C: The clinical spectrum of disease [J].
Hoofnagle, JH .
HEPATOLOGY, 1997, 26 (03) :S15-S20